|
|||||
|
|
| 罗格列酮对2型糖尿病患者颈动脉内膜中层厚度及血清可溶性血管细胞黏附分子-1水平的影响 | |
| 引用本文： | 赵永才,李新胜,张金成,钱红霞. 罗格列酮对2型糖尿病患者颈动脉内膜中层厚度及血清可溶性血管细胞黏附分子-1水平的影响[J]. 中国全科医学, 2011, 14(19) |
| 作者姓名： | 赵永才 李新胜 张金成 钱红霞 |
| 作者单位： | 河北省沧州市中心医院内分泌科,061001 |
| 摘 要： | 目的 观察2型糖尿病(T2DM)患者血清可溶性血管细胞黏附分子-1(sVCAM-1)水平和颈动脉内膜中层厚度(IMT)的变化,以及罗格列酮治疗对二者的影响.方法 将108例T2DM患者随机分为治疗组(54例)和对照组(54例).治疗组在原治疗基础上给予罗格列酮4 mg/d.治疗前和治疗6个月后检测血生化指标、IMT及血清sVCAM-1水平,并与对照组进行比较.结果 两组患者治疗后血糖均显著下降,差异有统计学意义(P＜0.05);治疗组治疗后IMT和sVCAM-1水平均较治疗前显著降低,差异有统计学意义(P＜0.05);对照组治疗后IMT和sVCAM-1水平与治疗前比较,差异无统计学意义(P＞0.05).多元线性逐步回归分析显示,IMT与sVCAM-1、BMI、2 hPG和HOMA-IR有关(P＜0.01).结论 血清sVCAM-1水平与T2DM早期大血管病变关系密切;罗格列酮能显著降低T2DM患者血清sVCAM-1水平,这可能是罗格列酮血管保护的作用机制之一. |
| 关 键 词： | 糖尿病,2型 颈动脉内膜中层厚度 可溶性血管细胞黏附分子-1 罗格列酮 |
Effects of Rosiglitazone on the IMT and Serum sVCAM-1 Levels in Type 2 Diabetic Patients |
|
| ZHAO Yong-cai,LI Xin-sheng,ZHANG Jin-cheng,et al.. Effects of Rosiglitazone on the IMT and Serum sVCAM-1 Levels in Type 2 Diabetic Patients[J]. Chinese General Practice, 2011, 14(19) | |
| Authors: | ZHAO Yong-cai LI Xin-sheng ZHANG Jin-cheng et al. |
| Affiliation: | ZHAO Yong-cai,LI Xin-sheng,ZHANG Jin-cheng,et al.The Centre Hospital of Cangzhou City,Cangzhou 061001,China |
| Abstract: | Objective To investigate the change of carotid intima-media thickness(IMT) and serum soluble vascular cell adhesion molecule-1(sVCAM-1) levels in Type 2 diabetic patients,and to assess the effect of rosiglitazone on IMT and sVCAM-1 levels.Methods In this study 108 cases of Type 2 diabetic patients were randomly divided into treatment group and control group,every group consisted of 54 numbers.The control group received routine therapy alone.The treatment group was treated with rosightazone 4 mg/d on the bas... |
| Keywords: | Diabetes mellitus type 2 Carotid intima-media thickness Soluble vascular cell adhesion molecule-1 Rosiglitazone |
| 本文献已被 CNKI 万方数据 等数据库收录！ | |